Rui Wang, M.D.

Rui Wang, M.D. is the Director of Patient Services (Asia) for ICAN, the International Cancer Advocacy Network (formerly known as the International Foundation for Anticancer Drug Discovery or IFADD). He graduated in 1987 from Xiangya School of Medicine in Changsha, one of the top medical schools in China.

After graduation he served as General Surgeon for six years at Beijing Chao Yang Hospital, a teaching hospital of Capital Medical University in Beijing, China. After coming to the United States in 1993, Dr. Wang served as a postdoctoral fellow at the Washington University School of Medicine in Saint Louis, Missouri.

Dr. Wang then joined the pharmaceutical company Pfizer and later the University of Nebraska Medical Center where he was involved in the development and research of several new drugs, including Celebrex.

王锐医师现任美国 International Cancer Advocacy Network 的亚洲部主任。1987 年他毕业于湖南长沙的湘雅医学院,中国最著名的医学院之一。毕业后,他在首都医科大学附属北京朝阳医院的普通外科担任了6年外科医生。1993 年来美国后,王医生先在美国密苏里州圣路易斯市的华盛顿大学医学院做博士后。随后他先后加盟美国辉瑞(Pfizer) 制药公司和内布拉斯加大学医学中心并参与了多种新药的研究和发展,其中包括已上市的新药西乐葆(Celebrex).

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Search only trustworthy HONcode health websites:

Federal Tax I.D.: EIN 86-0818253 | CA Registry of Charitable Trusts: CT0208668 | WA Charities: 37195

This website provides information about ICAN® Personalized Medicine Cancer Case Navigation Programs, while it also describes the ICAN® multi-faceted mission, unique vision, and respected values. Intended for use by the general public. This site also offers more in-depth information for target populations who may benefit from ICAN® Program Services such as ICAN® patients, their caregivers and medical teams — along with those healthcare professionals and researchers who are involved with ICAN® medical and scientific councils.

The health news displayed on this site are chosen by our team of M.D.s, PhDs, and ICAN® President and CEO, who is an Affiliate Member of ASCO, Read more...

the American Society of Clinical Oncology; AMP, the Association for Molecular Pathology; and AACR, the American Association for Cancer Research.

Information contained herein is therefore not intended to substitute for or supersede any advice that a patient receives from his/her health professional and is not intended to compromise in any way the patient-physician relationship. ICAN® strongly believes that all medical decisions need to be made, via shared decision-making, by the patient and his/her medical team.